DUBLIN–(BUSINESS WIRE)–Feb 17, 2021–
The "US Alzheimer’s Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com’s offering.
US Alzheimer’s Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026 Report Highlights:
- US Alzheimer’s Disease Drug Market Opportunity: > US$ 5 Billion
- US Accounts For More Than 40% of Global Alzheimer’s Disease Drug Market
- US Alzheimer’s Disease Drug Clinical Trials: 200 Drugs in Pipeline
- US Alzheimer’s Disease Drug Availability: 9 Branded & Several Generics
- Clinical Insight on 200 Alzheimer’s Disease Drug in Pipeline
- Marketed Branded/Generis/ Drugs Dosage, Patent, Price Insight
- 420 Page Comprehensive Insight on Clinical & Commercial Market Landscape
The US Alzheimer’s disease drug market is symbiotically and synergistically moving towards introducing innovative technologies and devices for building several different novel operating models for the disease market future. It can be witnessed for the US Alzheimer’s disease therapeutics market that the initial growth trend for the market, when compared with the current growth trend, is completely different. The market has been transformed by the protocols that were followed for the development of the drugs and therapies as well as different regulatory processes that made the entire procedure of drug approval difficult. In addition to it, the market is highly supported by other important parameters such as the introduction of a number of therapies for the patient population, increase in geriatric population in the country and technologically driven clinical research studies.
The market is now affiliated with an increase in the number of launches, which is estimated to shift the market towards approximately 50% growth in the next few years. Alzheimer’s drugs in the country also represent more than 50% of the medicines available for dementia conditions, thus making the entire market of Alzheimer’s disease the largest contributor of the dementia market. In addition to it, the market is supported by high drug research designations and breakthrough discoveries that will make the market appreciate more when compared to other dementia markets in the country.
As per "US Alzheimer’s Disease Drug Market, Dosage, Price & Clinical Trials Insight 2026" report findings, it is estimated that the US Alzheimer’s disease therapeutics market will be over-shadowing the growing trends and opportunities that can be observed for other emerging markets of the world. The availability of hundreds of blockbuster drugs for the patient population and robust clinical pipeline in the US research firms and bio-pharmaceutical companies are estimated to boost the overall market growth. The current Alzheimer’s disease therapeutics market is now looking forward to undergoing important and novel functional collaborations and partnerships that will ultimately lead to outsourcing of hundreds of novel drugs, diagnostic tools and therapies for US patient population as well as for global patients. The future share of the Alzheimer’s disease therapeutics market is estimated to increase at a very high rate, which will eventually strengthen the entire dominance level of US at a global level. Hundreds of novel investments for the development of the market is also holding promise to advance the entire market scenario and market trends that will support high-quality drugs for future patients.
Key Topics Covered:
1. US Alzheimer’s Disease Drug Market Overview
2. US – Approved Alzheimer’s Disease Drugs by Class
2.1 Cholinesterase Inhibitors
2.2 NMDA Receptor Agonist
3. US – New Emerging Therapies in Alzheimer’s Disease
3.1 Monoclonal Antibody
3.2 Novel NMDA Receptor Agonists
3.3 Small Molecules Drug
3.4 Oral Semaglutide
4. US – Alzheimer’s Disease Generic & Biosimilar Drug Market Landscape
5. Anti-Alzheimer’s Disease Drugs Classification
6. Acetylcholinesterases Inhibitor: US Market Availability, Dosage, Patent & Price Insight
6.1 Razadyne
6.2 Razadyne ER
6.3 Aricept
6.4 Aricept ODT
6.5 Reminyl
6.6 Exelon
6.7 Namzaric
7. N-methyl-D-aspartate Inhibitors: US Market Availability, Dosage, Patent & Price Insight
7.1 Namenda
7.2 Namenda XR
8. Approved Generic Drugs for Alzheimer’s: US Market Availability, Dosage & Price Insight
8.1 Galantamine
8.2 Donepzil
8.3 Rivastigmine
8.4 Memantine
8.5 Ergoloid Mesylates
9. US – Alzheimer’s Disease Drugs Clinical Trials Overview
10. US – Alzheimer’s Disease Drug Clinical Pipeline By Company, Indication & Phase
10.1 Unknown
10.2 Research
10.3 Preclinical
10.4 Clinical
10.5 Phase-I
10.6 Phase-I/II
10.7 Phase-II
10.8 Phase-II/III
10.9 Phase-III
10.10 Preregistration
10.11 Registered
11. US – Marketed Alzheimer’s Disease Drugs Clinical Insight
11.1 Razadyne
11.2 Namenda
11.3 Exelon Patch
11.4 Amyvid
11.5 Namzaric
11.6 Aricept
11.7 NeuraCeq
11.8 Vizamyl
11.9 Cognex
12. US Alzheimer’s Disease Drug Market Dynamics
12.1 US Alzheimer’s Market Favourable Parameters
12.2 US Alzheimer’s Drug Market Challenges
13. US Alzheimer Drug Market Future Prospects
14. Competitive Landscape
Companies Mentioned
- Allergan
- Alvogen
- Dr. Reddy Laboratories
- Eisai Co Ltd
- Hoffmann- La Roche Ltd
- Jassen Pharmaceuticals
- Lupin
- Mylan
- Novartis AG
- Sun Pharma
- Teva Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/j8mohw
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210217005655/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD: UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/17/2021 09:45 AM/DISC: 02/17/2021 09:45 AM
http://www.businesswire.com/news/home/20210217005655/en
